OptiBiotix Health Plc (LON:OPTI) CEO Stephen O’Hara talks to DirectorsTalk about it’s new strategy, the thinking behind this, what it means for shareholders and when we can expect to see a listing.
The company develop compounds which modify the human microbiome – the collective genome of the microbes in the body – to prevent and manage human disease.
Turner Pope Investments will be holding an Investor Evening this Monday 13th May 2019. With spaces limited it is important you reserve your spot via the email address at bottom. Venue:The Saloon, The Ned Hotel (www.thened.com), 27
NutraIngredients is pleased to announce the shortlisted finalists for the 2018 edition of the NutraIngredients Awards … with the winners announced at our exclusive awards evening in Geneva on 16th May. The shortlisted finalistsfor the 10
OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, and high cholesterol, today announced the launch of its award winning SlimBiome® in Nutri-Bites® with its US partner, Cereal Ingredients (“CII”), at the 2018 Natural
OptiBiotix Health PLC (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, today announced that it has entered into a production and commercialisation agreement with Fine Foods &
OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes announced on 28 November 2017 that it intended to seek a cancellation of its share premium account (the “Capital Reduction”) in
Optibiotix Health PLC (LON:OPTI) Chief Executive Officer Stephen O’Hara talks to tells Proactive Investors about focussing on the commercialisation of their technology across the company’s platforms.
Stephen O’Hara, CEO of OptiBiotix LON:OPTI commented: “We are pleased with the results of this study which showed OptiBiotix’s sweet oligosaccharide had the highest sweetness and was low in off-flavours when compared to a wide range
OptiBiotix Health plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity,high cholesterol, diabetes and skin care, announced this morning that it has had an abstract accepted for presentation at ProBiota 2018 in Barcelona from
OptiBiotix Health PLC (LON:OPTI), a specialist in the development of functional ingredients to modulate the human microbiome, has entered into a manufacturing and supply agreement with Cereal Ingredients. The agreement grants Cereal Ingredients a licence to
Slimbiome® is OptiBiotix’s patented combination of natural ingredients, identified and developed by leading experts in nutrition and metabolism, which supports scientifically substantiated weight loss claims. In independent tests the component ingredients have shown reductions in calorie intake
OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced today it has entered into a manufacturing and supply agreement with Cereal Ingredients, Inc, (“CII”). The agreement
Optibiotix Health CEO Stephen O’Hara commented “High blood pressure and high cholesterol are significant risk factors in cardiovascular disease. Numerous scientific studies have shown that In combination these factors work together to greatly increase the risk of
OptiBiotix Health PLC (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, today announced that subject to the completion of normal regulatory due diligence Neil Davidson CBE will be appointed as Non- Executive Chairman on 1 January 2018. Adam Reynolds, the current Non-Executive Chairman will
Following the announcement today from Kelloggs to cut the amount of sugar in its three top selling children’s cereals, we caught up with Stephen O’Hara, CEO of OptiBiotix Health PLC (LON:OPTI) for his thoughts: “We are really
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it intends to convene a General Meeting to seek shareholder consent to undertake a
Food Matters Live has announced the winners of its inaugural awards, which celebrate the incredible innovation that continues to shape the future of food and drink. These awards recognize the creativity and inventiveness of industry to
OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care gave DirectorsTalk the following product development and commercial update on its SlimBiome(R) product platform. Stephen O’Hara, CEO
OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced today it has entered into a manufacturing and supply agreement with Knighton Foods, The agreement grants
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.